Records containing: Neuroblastoma
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-04-13A Dose Escalation Study Using Eflornithine (DFMO) and AMXT 1501 Followed by a Randomized Controlled Trial of DFMO With or Without AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
-
CLINICAL_TRIALS study record update · 2026-04-13I-Metaiodobenzylguanidine (131 I-MIBG) Therapy for Refractory Neuroblastoma, Expanded Access Protocol
-
CLINICAL_TRIALS study record update · 2026-04-13LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors
-
CLINICAL_TRIALS study record update · 2026-04-09Phase I/II Study of Silmitasertib (CX-4945) in Combination With Chemotherapy in Children and Young Adults With Relapsed Refractory Solid Tumors
-
CLINICAL_TRIALS study record update · 2026-04-08Phase I Clinical Trial of Therapeutic Inducers of Natural Killer Killing (ThINKK) Adoptive Immunotherapy: Feasibility, Safety and Pharmacodynamics in Children Undergoing Allogenic Hematopoietic Transplantation for Leukemia or Neuroblastoma
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2026-04-08A Prospective Observational Study of Serial Circulating Tumor DNA and Molecular Residual Disease Monitoring for Molecular Profiling, Treatment Response Assessment, and Early Relapse Detection in Patients With Neuroblastoma
-
CLINICAL_TRIALS study record update · 2026-04-06Autologous Activated T-Cells Transduced With A 3rd Generation GD-2 Chimeric Antigen Receptor And iCaspase9 Safety Switch Administered To Patients With Relapsed Or Refractory Neuroblastoma (GRAIN)
-
CLINICAL_TRIALS study record update · 2026-04-03A Prospective Phase 3 Multi-center Study to Assess the Efficacy and Safety of 18F-mFBG PET Imaging in Subjects With Neuroblastoma
-
CLINICAL_TRIALS study record update · 2026-04-02Phase II Trial of a Bivalent Vaccine With the Immunological Adjuvant OPT-821 (QS-21), in Combination With Randomization of Oral β-glucan, for High-Risk Neuroblastoma
-
CLINICAL_TRIALS study record update · 2026-04-02Open Access Protocol of Targeted Radiotherapy With I-metaiodobenzylguanidine (I-MIBG) in Patients With Resistant Neuroblastoma or Malignant Chromaffin Cell Tumors
-
CLINICAL_TRIALS study record update · 2026-03-31Utility of Gallium-68-DOTA-Octreotate PET/CT in the Characterization of Pediatric Neuroendocrine Tumors
-
CLINICAL_TRIALS study record update · 2026-03-27A Phase I Study of Autologous Activated T-Cells Expressing a 2nd Generation GD2 Chimeric Antigen Receptor, IL-15, and iCaspase9 Safety Switch Administered To Patients With Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma
-
CLINICAL_TRIALS study record update · 2026-03-23N2004-05: Neuroblastoma Biology Study
-
CLINICAL_TRIALS study record update · 2026-03-23NANT N2013-02 A Phase I Study of Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma
-
CLINICAL_TRIALS study record update · 2026-03-23N2015-01: Neuroblastoma Precision Trial
-
CLINICAL_TRIALS study record update · 2026-03-23A Phase I Dose Escalation Study of Autologous Expanded Natural Killer (NK) Cells for Immunotherapy of Relapsed Refractory Neuroblastoma With Dinutuximab +/- Lenalidomide
-
CLINICAL_TRIALS study record update · 2026-03-23Phase II Study of Ex-Vivo Expanded Allogeneic Universal Donor TGFβi NK Cell Infusions in Combination With Temozolomide, Irinotecan, Dinutuximab, and Sargramostim in Patients With Relapsed or Refractory Neuroblastoma The STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
-
CLINICAL_TRIALS study record update · 2026-03-18An Open-Label, Dose Escalation, Efficacy, and Safety Study of CLR 131 in Children, Adolescents, and Young Adults With Select Solid Tumors, Lymphoma, and Malignant Brain Tumors
-
CLINICAL_TRIALS study record update · 2026-03-13Phase II Trial of a Bivalent Vaccine With the Immunological Adjuvant OPT-821 (QS-21), in Combination With Oral β-glucan and Randomization of GM-CSF, for High-risk Neuroblastoma
-
CLINICAL_TRIALS study record update · 2026-03-11Allogeneic Stem Cell Transplantation Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion With Zoledronic Acid in Combination to Treat Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory Solid Tumors
-
CLINICAL_TRIALS study record update · 2026-03-10Next Generation Personalized Neuroblastoma Therapy (The NEPENTHE Trial)
-
CLINICAL_TRIALS study record update · 2026-03-09PEACH TRIAL- Precision mEdicine and Adoptive Cellular tHerapy for the Treatment of Recurrent Neuroblastoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG)
-
CLINICAL_TRIALS study record update · 2026-03-02Phase II Trial of Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
-
CLINICAL_TRIALS study record update · 2026-02-27A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
-
CLINICAL_TRIALS study record update · 2026-02-27A Pilot Study of Intrathecal Topotecan and Maintenance Chemotherapy in the Post-consolidation Setting for the Treatment of High-risk Embryonal Central Nervous System Tumours in Children Less Than 6 Years of Age